Skip to content Skip to footer
Subscribe Now
Nutraceutical Top 20 2024
TOP 20

Top 20 Nutraceutical Companies of 2024

Shots: Nutraceuticals offer miraculous health benefits by enhancing body function and assisting in body repair and growth In 2023, the global Nutraceuticals market was valued at $419.93B and is expected to increase from $457.35B in 2024 to $976.74B by 2032 with a CAGR of 9.95 percent. Nestlé ranks first on our list with reported segment…
June 6, 2024

Read more

Diagnostic Top 20 2024
TOP 20

Top 20 Diagnostic Companies of 2024 

Shots:   Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace  In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue…
May 23, 2024

Read more

Medical Device Top 20 2024
TOP 20

Top 20 Medical Device Companies of 2024 

Shots:   Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received  With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…
May 9, 2024

Read more

RNAi Therapeutic Top 20 2024
TOP 20

Top 20 RNAi Therapeutic Companies of 2024

Shots:  RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines  In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…
April 25, 2024

Read more

Biopharm Top 20 2023
TOP 20

Top 20 Biopharma Companies of 2024

Shots: Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
April 11, 2024

Read more

Load more